Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41


PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers.

Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, Hurbain I, Raposo G, Popova T, Stern MH, Lallemand-Breitenbach V, Müller S, Cañeque T, Rodriguez R, Vincent-Salomon A, de Thé H, Rossignol R, Mechta-Grigoriou F.

Cell Metab. 2019 Jan 8;29(1):156-173.e10. doi: 10.1016/j.cmet.2018.09.002. Epub 2018 Sep 20.


Publisher Correction: RING tetramerization is required for nuclear body biogenesis and PML sumoylation.

Wang P, Benhenda S, Wu H, Lallemand-Breitenbach V, Zhen T, Jollivet F, Peres L, Li Y, Chen SJ, Chen Z, de Thé H, Meng G.

Nat Commun. 2018 May 4;9(1):1841. doi: 10.1038/s41467-018-04347-w.


PML nuclear bodies: from architecture to function.

Lallemand-Breitenbach V, de Thé H.

Curr Opin Cell Biol. 2018 Jun;52:154-161. doi: 10.1016/ Epub 2018 Apr 30. Review.


RING tetramerization is required for nuclear body biogenesis and PML sumoylation.

Wang P, Benhenda S, Wu H, Lallemand-Breitenbach V, Zhen T, Jollivet F, Peres L, Li Y, Chen SJ, Chen Z, de Thé H, Meng G.

Nat Commun. 2018 Mar 29;9(1):1277. doi: 10.1038/s41467-018-03498-0. Erratum in: Nat Commun. 2018 May 4;9(1):1841.


Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner.

Dubuisson L, Lormières F, Fochi S, Turpin J, Pasquier A, Douceron E, Oliva A, Bazarbachi A, Lallemand-Breitenbach V, De Thé H, Journo C, Mahieux R.

Oncogene. 2018 May;37(21):2806-2816. doi: 10.1038/s41388-018-0163-x. Epub 2018 Mar 6.


PML nuclear bodies, membrane-less domains acting as ROS sensors?

Niwa-Kawakita M, Wu HC, Thé H, Lallemand-Breitenbach V.

Semin Cell Dev Biol. 2018 Aug;80:29-34. doi: 10.1016/j.semcdb.2017.11.007. Epub 2017 Nov 20. Review.


PML is a ROS sensor activating p53 upon oxidative stress.

Niwa-Kawakita M, Ferhi O, Soilihi H, Le Bras M, Lallemand-Breitenbach V, de Thé H.

J Exp Med. 2017 Nov 6;214(11):3197-3206. doi: 10.1084/jem.20160301. Epub 2017 Sep 20.


Promyelocytic Leukemia Protein (PML) Controls Listeria monocytogenes Infection.

Ribet D, Lallemand-Breitenbach V, Ferhi O, Nahori MA, Varet H, de Thé H, Cossart P.

MBio. 2017 Jan 10;8(1). pii: e02179-16. doi: 10.1128/mBio.02179-16.


Promyelocytic Leukemia Protein, a Protein at the Crossroad of Oxidative Stress and Metabolism.

Tessier S, Martin-Martin N, de Thé H, Carracedo A, Lallemand-Breitenbach V.

Antioxid Redox Signal. 2017 Mar 20;26(9):432-444. doi: 10.1089/ars.2016.6898. Epub 2016 Dec 12. Review.


Detection of Protein SUMOylation In Situ by Proximity Ligation Assays.

Sahin U, Jollivet F, Berthier C, de Thé H, Lallemand-Breitenbach V.

Methods Mol Biol. 2016;1475:139-50. doi: 10.1007/978-1-4939-6358-4_10.


Comment on "SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML".

Ferhi O, Pérès L, Tessier S, de Thé H, Lallemand-Breitenbach V.

Sci Signal. 2016 Aug 9;9(440):tc1. doi: 10.1126/stke.9.440.tc1.


PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Sahin U, de Thé H, Lallemand-Breitenbach V.

Nucleus. 2014;5(6):499-507. doi: 10.4161/19491034.2014.970104. Review.


ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.

Dassouki Z, Sahin U, El Hajj H, Jollivet F, Kfoury Y, Lallemand-Breitenbach V, Hermine O, de Thé H, Bazarbachi A.

Blood. 2015 Jan 15;125(3):474-82. doi: 10.1182/blood-2014-04-572750. Epub 2014 Nov 13.


PML nuclear bodies: regulation, function and therapeutic perspectives.

Sahin U, Lallemand-Breitenbach V, de Thé H.

J Pathol. 2014 Nov;234(3):289-91. doi: 10.1002/path.4426. Review.


Interferon controls SUMO availability via the Lin28 and let-7 axis to impede virus replication.

Sahin U, Ferhi O, Carnec X, Zamborlini A, Peres L, Jollivet F, Vitaliano-Prunier A, de Thé H, Lallemand-Breitenbach V.

Nat Commun. 2014 Jun 19;5:4187. doi: 10.1038/ncomms5187.


Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins.

Sahin U, Ferhi O, Jeanne M, Benhenda S, Berthier C, Jollivet F, Niwa-Kawakita M, Faklaris O, Setterblad N, de Thé H, Lallemand-Breitenbach V.

J Cell Biol. 2014 Mar 17;204(6):931-45. doi: 10.1083/jcb.201305148.


Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?

Lallemand-Breitenbach V, de Thé H.

Blood. 2013 Sep 19;122(12):2008-10. doi: 10.1182/blood-2013-06-505115. Epub 2013 Jul 26.


Hematopoietic stem cells burn fat to prevent exhaustion.

Lallemand-Breitenbach V, de Thé H.

Cell Stem Cell. 2012 Oct 5;11(4):447-9. doi: 10.1016/j.stem.2012.09.008.


The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies.

de Thé H, Le Bras M, Lallemand-Breitenbach V.

J Cell Biol. 2012 Jul 9;198(1):11-21. doi: 10.1083/jcb.201112044. Review.


Curing APL through PML/RARA degradation by As2O3.

Lallemand-Breitenbach V, Zhu J, Chen Z, de Thé H.

Trends Mol Med. 2012 Jan;18(1):36-42. doi: 10.1016/j.molmed.2011.10.001. Epub 2011 Nov 4. Review.


[Forward - representation in life sciences: how technical evolution influenced our vision of life, from organism to single cell and molecule].

Lallemand-Breitenbach V.

Med Sci (Paris). 2010 Oct;26(10):881-2. doi: 10.1051/medsci/20102610881. French. No abstract available.


A new oncoprotein catabolism pathway.

Lallemand-Breitenbach V, de Thé H.

Blood. 2010 Sep 30;116(13):2200-1. doi: 10.1182/blood-2010-07-294025. No abstract available.


PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.

Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, Peres L, Berthier C, Soilihi H, Raught B, de Thé H.

Cancer Cell. 2010 Jul 13;18(1):88-98. doi: 10.1016/j.ccr.2010.06.003.


PML nuclear bodies.

Lallemand-Breitenbach V, de Thé H.

Cold Spring Harb Perspect Biol. 2010 May;2(5):a000661. doi: 10.1101/cshperspect.a000661. Epub 2010 Apr 21. Review.


Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z.

Science. 2010 Apr 9;328(5975):240-3. doi: 10.1126/science.1183424. Erratum in: Science. 2010 May 21;328(5981):974.


Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.

Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de Thé H.

Clin Cancer Res. 2009 Oct 15;15(20):6321-6. doi: 10.1158/1078-0432.CCR-09-0209. Epub 2009 Oct 6. Review.


["Pupils researchers", when the science opens its doors to the young people].

Lallemand-Breitenbach V.

Med Sci (Paris). 2009 Mar;25(3):293-6. doi: 10.1051/medsci/2009253293. French. No abstract available.


Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.

Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi PP, Rochette-Egly C, Zhu J, de Thé H.

Nat Med. 2008 Dec;14(12):1333-42. doi: 10.1038/nm.1891. Epub 2008 Nov 23. Erratum in: Nat Med. 2009 Jan;15(1):117.


Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.

Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de Thé H.

Nat Cell Biol. 2008 May;10(5):547-55. doi: 10.1038/ncb1717. Epub 2008 Apr 13.


CK2 and PML: regulating the regulator.

Lallemand-Breitenbach V, de Thé H.

Cell. 2006 Jul 28;126(2):244-5.


Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia.

Lallemand-Breitenbach V, Zhu J, Kogan S, Chen Z, de Thé H.

Nat Rev Cancer. 2005 Oct;5(10):821-7. Review.


CLIPR-59 is a lipid raft-associated protein containing a cytoskeleton-associated protein glycine-rich domain (CAP-Gly) that perturbs microtubule dynamics.

Lallemand-Breitenbach V, Quesnoit M, Braun V, El Marjou A, Poüs C, Goud B, Perez F.

J Biol Chem. 2004 Sep 24;279(39):41168-78. Epub 2004 Jul 19.


PML nuclear bodies and apoptosis.

Takahashi Y, Lallemand-Breitenbach V, Zhu J, de Thé H.

Oncogene. 2004 Apr 12;23(16):2819-24. Review.


In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.

Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V, Zhu J, Janin A, Daniel MT, Gourmel B, Degos L, Dombret H, Lanotte M, De Thé H.

J Exp Med. 2002 Nov 18;196(10):1373-80.


How acute promyelocytic leukaemia revived arsenic.

Zhu J, Chen Z, Lallemand-Breitenbach V, de Thé H.

Nat Rev Cancer. 2002 Sep;2(9):705-13. Review.


PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator.

Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de Thé H, Chelbi-Alix MK.

EMBO J. 2001 Jul 2;20(13):3495-505.


Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.

Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honoré N, Doubeikovsky A, Duprez E, Pandolfi PP, Puvion E, Freemont P, de Thé H.

J Exp Med. 2001 Jun 18;193(12):1361-71.


BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.

Kogan SC, Brown DE, Shultz DB, Truong BT, Lallemand-Breitenbach V, Guillemin MC, Lagasse E, Weissman IL, Bishop JM.

J Exp Med. 2001 Feb 19;193(4):531-43.


Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia.

Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de Thé H.

J Exp Med. 1999 Apr 5;189(7):1043-52.


SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.

Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de Thé H, Hay RT, Freemont PS.

J Cell Sci. 1999 Feb;112 ( Pt 3):381-93.

Supplemental Content

Loading ...
Support Center